Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 14 years of Total Non-Current Liabilities data on file, last reported at $345.6 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $345.6 million, up 191.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $345.6 million (up 191.03% YoY), and the FY2025 annual result was $346.6 million, up 192.28% from the prior year.
• Total Non-Current Liabilities steadied at $345.6 million in Q1 2026 per MDGL's latest filing, from $346.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $346.6 million in Q4 2025 and troughed at $283000.0 in Q1 2022.
• A 5-year average of $136.1 million and a median of $117.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities fell 26.87% in 2022, then soared 29569.61% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $49.3 million in 2022, then jumped by 136.7% to $116.7 million in 2023, then grew by 1.65% to $118.6 million in 2024, then soared by 192.28% to $346.6 million in 2025, then declined by 0.29% to $345.6 million in 2026.
• Business Quant data shows MDGL's Total Non-Current Liabilities at $345.6 million in Q1 2026, $346.6 million in Q4 2025, and $345.3 million in Q3 2025.